However, the drug Mecasermin targeting IGFBP1 has been approved to treat growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion and is likely to be used for treating obesity. Here, GH1 is linked to obesity due to melanocortin 4 receptor deficiency.